Navigation Links
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced encouraging results in an ongoing Dana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. To date, 10 patients were evaluable for best overall tumor response (assessed at least after 8 weeks / 2 chemotherapy cycles), whereby all 10 women had previously failed three lines of chemotherapy (starting fourth line). 1 patient had a partial response, 5 stable disease and 4 progressive disease. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

The primary objective of this open-label single-arm Phase 2 is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women may be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. A link to the trial description and contact information is available at www.novelos.com under 'Clinical Trials' section.

"I am encouraged by these preliminary results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients," said Dr. Carolyn Krasner, the Principal Investigator. "Most women, having failed three lines of chemotherapy, would be expected to progress in about eight weeks."

"We look forward to continuing to work closely with Dana-Farber/Partners on developing NOV-002 for this indication," said Harry Palmin, President and CEO of Novelos. "Meanwhile, Novelos remains on-track for full enrollment of our pivotal Phase 3 trial of NOV-002 for lung cancer in the first quarter 2008."

Acco
'"/>




Page: 1 2 3

Related medicine technology :

1. Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
(Date:9/2/2015)... MARIETTA, Ga. , Sept. 2, 2015  MiMedx ... regenerative medicine company utilizing human amniotic tissue and ... and therapies for the Wound Care, Surgical, Orthopedic, ... healthcare, today corrected the inaccurate statements published by ... release of September 1, 2015. MTF,s ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... Inc., a privately,held biopharmaceutical company that specializes ... ophthalmic,pharmaceuticals, today reported the interim month three ... pharmacokinetic (PK) study of Medidur(TM) FA,which Alimera ... Iluvien(TM),if approved by the U.S. Food and ...
... developing proposals to fund clinical studies for early detection ... ... 25 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ), a ... the Small,Business Innovation Research (SBIR) and Small Business Technology Transfer,(SBTT) seed ...
Cached Medicine Technology:Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 2Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 3Small Business Innovation Research Program Awards Grant to Biomoda 2
(Date:9/3/2015)... ... 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... perspective on internal medicine keeps patients happy and healthy, something that is important to ... the season, but even more so in the fall, when holiday eating and seasonal ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... Lauderdale, FL (PRWEB) , ... September 02, 2015 ... ... for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by ... hospitalized Medicare patients – is likely to average approximately $71,000 or roughly 40% ...
Breaking Medicine News(10 mins):Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... study to identify the composition of bacterial populations on the ... Skin, which// is the largest organ in our body harbors ... previously. Researchers said that it appears that the skin, is ... quite novel. ,Researchers found evidence for 182 species ...
... during pregnancy could lead to diabetes and cardio vascular ... women. Among them, those who had a high BP ... atherosclerosis than their counterparts who had a normal BP. ... latest issue of ‘Hypertension’ suggests that calcification of the ...
... latest Government data, there is an alarming rise in suicides ... linked to the plummeting sale of// antidepressants. ,This ... also indicated that youth in their late teens resorted to ... Administration had issued a black box warning on the antidepressants ...
... conducted by Robert Wilson of Rush University Medical Centre of Chicago ... Alzheimer’s like// Dementia. People who are single or socially secluded are ... their life. ,According to this study, a group of ... age group of 80 for a period of four years. A ...
... Worldwide describes a lawsuit from CSPI -Center for Science in ... claims of their new drink. ,According to the ... more calories and hence, an aid to calorie ... soft drink is laced with EGCG or epigallocatechin gallate which ...
... pain in the jaw may be a sign of a heart ... Uruguay.// ,The symptoms are however often overlooked, and especially ... tooth or jaw ache without chest pains, the study said. ... were asked to indicate on a body chart where they experienced ...
Cached Medicine News:Health News:Human Skin Harbors Many More Types of Bacteria 2Health News:Human Skin Harbors Many More Types of Bacteria 3Health News:Human Skin Harbors Many More Types of Bacteria 4Health News:Human Skin Harbors Many More Types of Bacteria 5Health News:Support Claims With Science Not Magic, Beverage Owners Warned 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: